VANCOUVER, Oct. 17, 2018 /CNW/ - RepliCel Life Sciences Inc.
(OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ("RepliCel" or the "Company"),
a company developing next-generation technologies in aesthetics and
orthopedics, announces that its board of directors has appointed
Simon Ma as the Chief Financial
Officer of the Company. Mr. Ma is the current Director of
Finance and succeeds Tom Kordyback
who has resigned as the Chief Financial Officer to enjoy his
full-time retirement from professional service.
Mr. Ma is a Chartered Professional Accountant and has extensive
experience with private and public companies. He graduated from the
University of British Columbia in 1987
and obtained a degree of Bachelor of Arts in Economics after which
he worked in the industry as a Controller until1990 when he started
articling. He qualified as a Chartered Accountant in 1994.
Simon Ma has been a sole public
practitioner since 1997 and is practicing under the name of Simon
S. Ma Corporation. He is concurrently serving as chief financial
officer of several public companies listed on the TSX Venture
Exchange or the Canadian Securities Exchange. He has also
been the Director of Finance of the Company since June 2016.
The Company would like to thank Mr. Kordyback for his service
and dedication to the Company. He remains a material shareholder of
RepliCel and will remain as a consultant to the Company on matters
of finance and corporate strategy.
"As RepliCel prepares itself for an exciting new phase of
development and commercialization, we will be strengthening our
management team to execute programs, fulfil partnership
commitments, deliver milestones and create value for shareholders,"
stated RepliCel President & CEO, R. Lee
Buckler. "Tom has been a tremendous asset to the Company and
has been critical in preparing Simon for the role he has now taken
as part of RepliCel management. I look forward to working with
Simon in this new capacity."
About RepliCel Life Sciences
RepliCel is a
regenerative medicine company focused on developing cell therapies
for aesthetic and orthopedic conditions affecting what the Company
believes is approximately one in three people in industrialized
nations, including aging/sun-damaged skin, pattern baldness, and
chronic tendon degeneration. These conditions, often
associated with aging, are caused by a deficit of healthy cells
required for normal tissue healing and function. The Company's
product pipeline is comprised of RCT-01 for tendon repair, RCS-01
for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is
currently being co-developed with, and under exclusive license by,
Shiseido for certain Asian countries. All product candidates are
based on RepliCel's innovative technology, utilizing cell
populations isolated from a patient's healthy hair follicles.
RepliCel has also developed a proprietary injection device, RCI-02,
optimized for the administration of its products and licensable for
use with other dermatology applications. Please
visit www.replicel.com for additional information.
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in policies
of the TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/replicel-life-sciences-appoints-new-chief-financial-officer-300731410.html
SOURCE RepliCel Life Sciences Inc.
